StemRIM (TYO:4599) has amended the protocol for the global late-stage phase two clinical trial of Redasemtide for the treatment of acute ischemic stroke (AIS), according to a Monday filing with the Tokyo Stock Exchange.
The change includes adding a new group of patients who have undergone endovascular recanalization therapy to the study.
The biotechnology company will also relax the eligibility criteria for the participating patients without significantly extending the trial period.
The company said the move aims to address changes in the treatment paradigm for AIS and the rise in the number of eligible patients.
Price (JPY): $345.00, Change: $-5.0, Percent Change: -1.43%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。